Fig. 4.
MYC confers resistance to pharmacological PI3K or mTOR inhibitors. (A) Schematic representation of the PI3K-mTOR pathway with the inclusion of kinase inhibitors used in this study. (B–D) Growth curves of HMECs expressing empty vector, PIK3CA(H1047R), MYC, PIK3CA(H1047R)+MYC, or the Enriched cells grown in (B) 50 nM BEZ235 (control) or 1.5 μM GDC0941, (C) 200 nM rapamycin or 1 μM Ku-0063794, or (D) 10 nM Paclitaxel. (Data are represented as mean ± SEM.)